Condition 1: Polycystic Ovary Syndrome. Condition 2: Sexual Dysfunction.
Conditions
Interventions
Intervention 1: LD combined oral contraceptive pills produced by Iran Hormone company are consumed for 3 months, 21 days each month from the second day of the menstrual period, then the medication is
Sponsors
Tarbiat Modares University
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: ) Iranian women age 18- 404 years , 2) PCOS based on Rotterdam criteria (19), 3) women having Vitamin D3 level less than 20 ng/ml (base on the test), 4) women having sex in the last month, and 5) women who used non-hormonal contraceptives three months before the start of the study
Exclusion criteria
Exclusion criteria: included having the history of side effects (such as headache, vomiting from OCP), chronic diseases, including diabetes mellitus, hypertension, Vascular-Thrombi-Embolism (VTE), and thyroid, having the history for sterility, having no history of depression based on Beck Depression Inventory (BDI) questionnaire, having intention to conceive in near future, no need for OCP treatment, the having no history of Cushing's syndrome, adrenal hyperplasia, and adrenal tumor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sexual Fanction Score obtained in the Female Sexual Function Index (FSFI) questionnaire. Timepoint: At the start of the study and 3 and 6 months from the start of the treatment. Method of measurement: Female Sexual Function Index (FSFI) questionnaire.;The level of vitamin D 3 in the blood. Timepoint: At the start of the study and 3 and 6 months from the start of the treatment. Method of measurement: Biochemical examination of blood. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactD Shahideh Jahanian Sadatmahale
Tarbiat Modares University
Outcome results
None listed